Critical Reviews in Clinical Laboratory Sciences

Papers
(The TQCC of Critical Reviews in Clinical Laboratory Sciences is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
The COVID-19 pandemic802
COVID-19: from an acute to chronic disease? Potential long-term health consequences226
Current concepts and advances in biomarkers of acute kidney injury84
The COVID-19 pandemic: viral variants and vaccine efficacy68
Vitamin B12status in health and disease: a critical review. Diagnosis of deficiency and insufficiency – clinical and laboratory pitfalls67
Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review60
Vitamin D: sources, physiological role, biokinetics, deficiency, therapeutic use, toxicity, and overview of analytical methods for detection of vitamin D and its metabolites59
Potential value and impact of data mining and machine learning in clinical diagnostics56
Molecular diagnostic assays for COVID-19: an overview49
Recent evolutions of machine learning applications in clinical laboratory medicine26
Molecular tissue profiling by MALDI imaging: recent progress and applications in cancer research25
The molecular structure and biological functions of RNA methylation, with special emphasis on the roles of RNA methylation in autoimmune diseases25
The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome24
Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath24
Nucleic acid-based electrochemical biosensors for rapid clinical diagnosis: advances, challenges, and opportunities23
Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-1920
What the lab can and cannot do: clinical interpretation of drug testing results20
Liquid biopsy with cell free DNA: new horizons for prostate cancer18
The potential impact of salivary peptides in periodontitis18
T helper cells in depression: central role of Th17 cells18
Oligoclonal bands: clinical utility and interpretation cues18
Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future17
Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology16
Systematic review and meta-analysis of C-reactive protein as a biomarker in breast cancer15
Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS)15
CRISPR-based biosensing systems: a way to rapidly diagnose COVID-1915
Smartphone technology facilitates point-of-care nucleic acid diagnosis: a beginner’s guide14
Development of circulating microRNA-based biomarkers for medical decision-making: a friendly reminder of what should NOT be done14
Identifying and overcoming barriers to harmonize newborn screening programs through consensus strategies14
DropWise: current role and future perspectives of dried blood spots (DBS), blood microsampling, and their analysis in sports drug testing14
Lean and Six Sigma as continuous quality improvement frameworks in the clinical diagnostic laboratory13
Clinical utility of procalcitonin and its association with pathogenic microorganisms12
Progress in understanding COVID-19: insights from the omics approach12
0.019937992095947